Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters

Horacio B. Croxatto, M. R. Massai, A. M. Salvatierra, B. Fuentealba, H. D. Croxatto, P. Lähteenmäki

Resultado de la investigación: Article

13 Citas (Scopus)

Resumen

The efficacy of a low dose of mifepristone, 5 mg/day for the first 15 days of the menstrual cycle, followed by medroxyprogesterone acetate (MPA), 10 mg/day for the next 13 days, for inhibiting ovulation was assessed in ten volunteers who were treated for three successive cycles. Hormonal determinations in blood and urine samples, ovarian ultrasonography and an endometrial biopsy taken on day 21-24 of the third treatment cycle were used to monitor the cycles. Ovulation was confirmed in 11 of the 30 treated cycles and, in these 11, the LH peak and follicular rupture occurred during MPA treatment periods. Out of 19 anovulatory cycles, 16 had no increase in progesterone levels and another 3 developed a luteinized unruptured follicle. Progestin administration induced secretory changes in the endometrium, but irregular or delayed development was found. Regular withdrawal bleeding occurred in all subjects. These data indicate that the sequential regimen can suppress ovulation while maintaining regular bleeding but increased efficacy is needed for phase II clinical trials.

Idioma originalEnglish
Páginas (desde-hasta)79-86
Número de páginas8
PublicaciónContraception
Volumen54
N.º2
DOI
EstadoPublished - 1 ene 1996

Huella dactilar

Mifepristone
Medroxyprogesterone Acetate
Ovulation
Hemorrhage
Phase II Clinical Trials
Progestins
Menstrual Cycle
Endometrium
Progesterone
Rupture
Volunteers
Ultrasonography
Urine
Biopsy
Therapeutics

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Citar esto

Croxatto, Horacio B. ; Massai, M. R. ; Salvatierra, A. M. ; Fuentealba, B. ; Croxatto, H. D. ; Lähteenmäki, P. / Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. En: Contraception. 1996 ; Vol. 54, N.º 2. pp. 79-86.
@article{502be32860cf4a16b89caf2dc55eb840,
title = "Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters",
abstract = "The efficacy of a low dose of mifepristone, 5 mg/day for the first 15 days of the menstrual cycle, followed by medroxyprogesterone acetate (MPA), 10 mg/day for the next 13 days, for inhibiting ovulation was assessed in ten volunteers who were treated for three successive cycles. Hormonal determinations in blood and urine samples, ovarian ultrasonography and an endometrial biopsy taken on day 21-24 of the third treatment cycle were used to monitor the cycles. Ovulation was confirmed in 11 of the 30 treated cycles and, in these 11, the LH peak and follicular rupture occurred during MPA treatment periods. Out of 19 anovulatory cycles, 16 had no increase in progesterone levels and another 3 developed a luteinized unruptured follicle. Progestin administration induced secretory changes in the endometrium, but irregular or delayed development was found. Regular withdrawal bleeding occurred in all subjects. These data indicate that the sequential regimen can suppress ovulation while maintaining regular bleeding but increased efficacy is needed for phase II clinical trials.",
keywords = "antiprogestin, bleeding pattern, endometrium, mifepristone, ovulation inhibition, progestin, RU486",
author = "Croxatto, {Horacio B.} and Massai, {M. R.} and Salvatierra, {A. M.} and B. Fuentealba and Croxatto, {H. D.} and P. L{\"a}hteenm{\"a}ki",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/0010-7824(96)00138-2",
language = "English",
volume = "54",
pages = "79--86",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "2",

}

Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. / Croxatto, Horacio B.; Massai, M. R.; Salvatierra, A. M.; Fuentealba, B.; Croxatto, H. D.; Lähteenmäki, P.

En: Contraception, Vol. 54, N.º 2, 01.01.1996, p. 79-86.

Resultado de la investigación: Article

TY - JOUR

T1 - Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters

AU - Croxatto, Horacio B.

AU - Massai, M. R.

AU - Salvatierra, A. M.

AU - Fuentealba, B.

AU - Croxatto, H. D.

AU - Lähteenmäki, P.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The efficacy of a low dose of mifepristone, 5 mg/day for the first 15 days of the menstrual cycle, followed by medroxyprogesterone acetate (MPA), 10 mg/day for the next 13 days, for inhibiting ovulation was assessed in ten volunteers who were treated for three successive cycles. Hormonal determinations in blood and urine samples, ovarian ultrasonography and an endometrial biopsy taken on day 21-24 of the third treatment cycle were used to monitor the cycles. Ovulation was confirmed in 11 of the 30 treated cycles and, in these 11, the LH peak and follicular rupture occurred during MPA treatment periods. Out of 19 anovulatory cycles, 16 had no increase in progesterone levels and another 3 developed a luteinized unruptured follicle. Progestin administration induced secretory changes in the endometrium, but irregular or delayed development was found. Regular withdrawal bleeding occurred in all subjects. These data indicate that the sequential regimen can suppress ovulation while maintaining regular bleeding but increased efficacy is needed for phase II clinical trials.

AB - The efficacy of a low dose of mifepristone, 5 mg/day for the first 15 days of the menstrual cycle, followed by medroxyprogesterone acetate (MPA), 10 mg/day for the next 13 days, for inhibiting ovulation was assessed in ten volunteers who were treated for three successive cycles. Hormonal determinations in blood and urine samples, ovarian ultrasonography and an endometrial biopsy taken on day 21-24 of the third treatment cycle were used to monitor the cycles. Ovulation was confirmed in 11 of the 30 treated cycles and, in these 11, the LH peak and follicular rupture occurred during MPA treatment periods. Out of 19 anovulatory cycles, 16 had no increase in progesterone levels and another 3 developed a luteinized unruptured follicle. Progestin administration induced secretory changes in the endometrium, but irregular or delayed development was found. Regular withdrawal bleeding occurred in all subjects. These data indicate that the sequential regimen can suppress ovulation while maintaining regular bleeding but increased efficacy is needed for phase II clinical trials.

KW - antiprogestin

KW - bleeding pattern

KW - endometrium

KW - mifepristone

KW - ovulation inhibition

KW - progestin

KW - RU486

UR - http://www.scopus.com/inward/record.url?scp=0030222227&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(96)00138-2

DO - 10.1016/0010-7824(96)00138-2

M3 - Article

C2 - 8842583

AN - SCOPUS:0030222227

VL - 54

SP - 79

EP - 86

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 2

ER -